Can a Two-Step stem cell transplant tame Graft-Versus-Host disease?

NCT ID NCT03712878

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 2 trial tests a two-step approach to stem cell transplantation for people with blood cancers. The method separates the infusion of donor lymphocytes from stem cells, aiming to better control the dose and reduce the risk of graft-versus-host disease, a serious complication. Participants receive chemotherapy and total-body radiation before the transplant, followed by drugs to suppress immune reactions. The study focuses on whether this strategy can achieve high levels of donor immune cells in the patient's body quickly and safely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a two-step stem cell transplant with total-body irradiation, donor lymphocyte infusion, and cyclophosphamide
What this could lead to
If successful, this approach could make stem cell transplants safer and more effective for people with blood cancers, potentially leading to higher cure rates with fewer complications.
What could go wrong
This is a small early-phase trial, so results may not apply broadly. Risks include graft-versus-host disease, infection, and transplant failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.